Today is Tuesday and it is raining heavily in Wuhan, I came to the medical oncology clinic on time at 8:30 am and there were many new and old patients waiting in the clinic. Among the waiting patients, there was a patient from Huangshi, less than 50 years old, tall and big, weighing 83 kg after hospitalization, who really did not look like a patient on the surface. I did a bone ECT scan on him in the clinic and he had bone metastases in many places throughout his body. I felt sorry for him, the reason is, he is a patient after right lung adenocarcinoma surgery, the surgery has removed the tumor completely and the regional lymph nodes have been cleared, he should have done adjuvant chemotherapy after surgery in the real sense. However, instead of doing chemotherapy, he went on oral erlotinib for 4 months, sending his condition straight to the advanced stage. It wasn’t the doctor who wanted him to take oral erlotinib, it was the patient’s family. The patient’s family heard that Erlotinib was effective in treating lung cancer, so they went to buy it and asked the patient to take it orally at home. The patient’s family was very remorseful and in tears, but it was already too late and good intentions made a big mistake. The post-operative adjuvant therapy for non-small cell lung cancer that can give patients therapeutic benefit is post-operative adjuvant chemotherapy/ and adjuvant radiotherapy. Neither small molecule TKI inhibitors such as Eretzac or Troche have been able to benefit patients on adjuvant therapy, and are worse off with the drug later compared to no treatment. Postoperative adjuvant therapy benefits patients by reducing the incidence of recurrent metastases or prolonging the time to recurrent metastases, and small molecule TKI inhibitors shorten the time to recurrent metastases compared to placebo. One of the advances in the treatment of advanced non-small cell lung cancer is the introduction of small molecule TKI agents, such as ERSA or Troche, which have indeed enabled some patients with advanced non-small cell lung cancer to prolong their lives, reduce or eliminate tumor-related symptoms, and improve their quality of life, making long-term survival with tumor in advanced non-small cell lung cancer no longer a dream. However, the population benefiting from the treatment, which is limited to patients with advanced stages, is only for patients with mutations in the EGFR gene. Using a drug that is effective in the treatment of advanced non-small cell lung cancer for adjuvant chemotherapy after early surgery should theoretically be effective, but clinical trials have come to the opposite conclusion. Repeated trials have again argued that adjuvant treatment with ERSA or Troche after surgery for early-stage non-small cell lung cancer is harmful. The platinum-containing two-drug combination chemotherapy remains the gold standard for post-operative adjuvant therapy for non-small cell lung cancer.